US 12252530
Human antibodies to Fel d1 and methods of use thereof
granted A61KA61K2039/505A61K2039/507
Quick answer
US patent 12252530 (Human antibodies to Fel d1 and methods of use thereof) held by REGENERON PHARMACEUTICALS, INC. expires Mon Mar 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- REGENERON PHARMACEUTICALS, INC.
- Grant date
- Tue Mar 18 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Mar 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 32
- CPC classes
- A61K, A61K2039/505, A61K2039/507, A61K2039/5252, A61K39/12